Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic mesenchymal stromal cells
- Development stage
- Preclinical
- Lead developer
- LifeStem
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intrathecal
01
Overview
Allogeneic mesenchymal stromal cells (MSCs) are an investigational cell therapy being developed by LifeStem for the treatment of Type III Spinal Muscular Atrophy (SMA). These cells are typically derived from healthy donor sources, such as umbilical cord tissue or bone marrow, and are administered to patients to leverage their neuroprotective and immunomodulatory properties. In the context of SMA, the therapy is designed to support the survival of motor neurons by secreting a variety of neurotrophic factors, including brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF). These factors help maintain neuronal plasticity and reduce the rate of degeneration. Additionally, the cells modulate the inflammatory microenvironment within the spinal cord, potentially slowing disease progression and improving motor function in patients with Type III SMA.
- Other names
- allogenic mesenchymal stromal cellsallogeneic mesenchymal stem cellsallogenic mesenchymal stem cellsLifeStem allogeneic MSC therapy
Beyond the preview
Go deeper on allogeneic mesenchymal stromal cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic mesenchymal stromal cells.